
Orphazyme's newly appointed CEO Christophe Bourdon certainly does not lack ambition. Within the next ten years, he sees potential for turning Orphazyme into the new Genmab – but with a focus on rare diseases, according to Danish newspaper Børsen.
Before reaching this point, however, he plans to start remedying the disappointment which the company recently had in a clinical trial for the muscle-wasting disease Inclusion Body Myositis (IBM), which caused the firm's share price to plummet.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app